A non­prof­it group’s Cha­gas drug beat out Mar­tin Shkre­li's old ri­val to FDA OK, valu­able PRV

Sil­via Gold, Mun­do Sano

The FDA has ap­proved a new drug for Cha­gas dis­ease, but one of Mar­tin Shkre­li’s for­mer biotechs — which set its sights on Cha­gas — isn’t the one ben­e­fit­ing from the mar­ket­ing OK. And Shkre­li’s suc­ces­sors say they now have to switch up their game plan af­ter the ri­val group snagged the valu­able pri­or­i­ty re­view vouch­er that came with the first OK, blast­ing their share price.

The non­prof­it drug de­vel­op­ment or­ga­ni­za­tion Drugs for Ne­glect­ed Dis­eases ini­tia­tive (DNDi), along with the phar­ma­ceu­ti­cal com­pa­ny Chemo Group and the non­prof­it foun­da­tion Mun­do Sano set out a year ago to reg­is­ter the drug in ar­eas where its need­ed, in­clud­ing the US.

Now Chemo Re­search SL, a unit of the Chemo Group, has won the first ever US OK for the drug — for pe­di­atric pa­tients — along with a pri­or­i­ty re­view vouch­er that’s like­ly worth over $100 mil­lion.

The non­prof­its band­ed to­geth­er with the ex­press mis­sion of mak­ing the ther­a­py avail­able at cost, plus what they said would be a rea­son­able mar­gin. They al­so pledged that half of any mon­ey they get from the PRV will be ear­marked for Mun­do Sano’s non­prof­it work. The FDA state­ment on the ap­proval notes that while Cha­gas is en­dem­ic in Latin Amer­i­ca, some 300,000 peo­ple have it in the US.

That’s what at­tract­ed Mar­tin Shkre­li to the drug. Af­ter he ac­quired Kalo­Bios out of bank­rupt­cy, he land­ed the world­wide rights to a ver­sion of the same drug with plans to boost the price — from $50 to $100 in Latin Amer­i­ca and free from the CDC — up to then hep C lev­els, which were $60,000 to $90,000.

Shkre­li’s most no­to­ri­ous for his work at Tur­ing, where he bought an­oth­er old drug and hiked the price more than 5000%.

Shkre­li was lat­er charged with fraud — re­cent­ly con­vict­ed on three felony counts — and had to ex­it Kalo­Bios, which sub­se­quent­ly changed its name to Hu­mani­gen $HGEN and barred Shkre­li from the premis­es.

In an SEC post Wednes­day morn­ing, though, Hu­mani­gen — now run by Cameron Dur­rant — says the ap­proval for the ri­val group means they are out of the run­ning on the PRV, rais­ing ques­tions about the fu­ture of their work.

As a re­sult of FDA’s ac­tions and with the in­for­ma­tion cur­rent­ly avail­able, Hu­mani­gen, Inc. no longer ex­pects to be el­i­gi­ble to re­ceive a PRV with its own ben­znida­zole can­di­date for the treat­ment of Cha­gas dis­ease. Ac­cord­ing­ly, Hu­mani­gen is as­sess­ing its op­tions in re­spect of that de­vel­op­ment pro­gram and the com­pa­ny’s mon­o­clon­al an­ti­bod­ies, lenzilum­ab and ifabo­tuzum­ab.
That’s not what share­hold­ers want­ed to hear. Hu­mani­gen’s shares im­plod­ed on the news, with the OTC stock drop­ping 73% and plung­ing deep in­to pen­ny stock ter­ri­to­ry.

Ac­cord­ing to a spokesper­son at DNDi, “one of the first ac­tiv­i­ties in this strate­gic col­lab­o­ra­tion was the de­vel­op­ment of an ur­gent­ly need­ed sec­ond source of the pe­di­atric dosage form of ben­znida­zole, fol­low­ing dis­rup­tions in sup­ply from what at the time was the on­ly ex­ist­ing child-adapt­ed for­mu­la­tion of ben­znida­zole.”

DN­Di’s Ex­ec­u­tive Di­rec­tor Bernard Pé­coul had this to say:

Glob­al­ly, few­er than 1% of the six to eight mil­lion peo­ple with Cha­gas dis­ease have ac­cess to treat­ment. In the U.S. on­ly a hand­ful of pa­tients have had ac­cess to treat­ment, thanks to the ef­forts of lead­ing Cha­gas clin­i­cians in places like Los An­ge­les and north­ern Vir­ginia. It is our hope that pa­tients in the U.S. will now have eas­i­er ac­cess to ben­znida­zole, and that FDA reg­is­tra­tion will al­so cat­alyze en­dem­ic coun­tries in Latin Amer­i­ca that have not yet reg­is­tered the drug to do so.

“The FDA is com­mit­ted to mak­ing avail­able safe and ef­fec­tive ther­a­peu­tic op­tions to treat trop­i­cal dis­eases,” said Ed­ward Cox, di­rec­tor of the Of­fice of An­timi­cro­bial Prod­ucts in the FDA’s CDER.

UP­DAT­ED: Roche bags 'break­through' an­ti-fi­bro­sis drug in $1.4B biotech buy­out deal

Roche is snapping up a “breakthrough” anti-fibrotic drug in a $1.4 billion buyout.

The pharma giant announced Friday that it is acquiring Promedior, primarily to get its hands on PRM-151, a recombinant form of human pentraxin-2 (PTX-2) protein that has nailed down mid-stage clinical data on idiopathic pulmonary fibrosis and demonstrating its potential for a range of fibrotic conditions.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,700+ biopharma pros reading Endpoints daily — and it's free.

(Image: Associated Press)

Amarin emerges from an ex­pert pan­el re­view with a clear en­dorse­ment for Vas­cepa and high odds of suc­cess when the FDA weighs in for­mal­ly

Several FDA experts who gathered Thursday to consider the landmark approval of Vascepa to reduce cardio events in an at-risk population voiced their unease about various aspects of the efficacy and safety data, or ultimately the population it should be used to treat. But the overwhelming belief that the data pointed to the drug’s benefit and clearly outweighed risks carried the day for Amarin.

The panel voted unanimously (16 to 0) to support the company’s positive data presentation — backing an OK for expanding the label to include reducing cardio risk. The vote points Amarin $AMRN down a short path to a formal decision by the FDA, with the odds heavily in its favor. Chances are the rest of the questions about the future of this drug will be hashed out in the label’s small print.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,700+ biopharma pros reading Endpoints daily — and it's free.

Federal Trade Commission commissioner Rohit Chopra testifies on Capitol Hill (AP Photo/Susan Walsh)

FTC clears Bris­tol-My­ers’ $74B deal to buy Cel­gene — but Dems sig­nal a po­ten­tial hard shift against Big Phar­ma M&A

Bristol-Myers Squibb’s record $74 billion takeover of Celgene is a done deal. And it will all be over — except for the lingering complaints from die-hard Celgene investors — on Wednesday.

Like much else that’s going on in Washington these days, the vote among the 5 FTC commissioners split along party lines, with the 3 Republicans voting to clear the way and the 2 Democrats steamed over what they see as a major M&A move that will lessen competition and innovation. And that split has big implications for the M&A side of the business if the Dems take the White House in 2020.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,700+ biopharma pros reading Endpoints daily — and it's free.

No­var­tis spin­out’s first an­ti-ag­ing PhI­II is a flop, so now they’ll turn to Parkin­son’s chal­lenge as shares wilt

Novartis spinout resTORbio is grappling with the collapse of its lead clinical program this morning — an anti-aging R&D failure that will badly damage their rep in the field.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,700+ biopharma pros reading Endpoints daily — and it's free.

BeiGene CEO John Oyler at an Endpoints event in Shanghai, October 2018 (Credit: Endpoints News/PharmCube)

UP­DAT­ED: In a first, FDA green-lights use of a Chi­nese built can­cer ther­a­py — and more are com­ing

Weeks after Amgen took a $2.7 billion stake in BeiGene, the Beijing-based biotech has secured its first-ever FDA approval for zanubrutinib, a BTK inhibitor, months ahead of schedule.

BeiGene’s drug, branded as Brukinsa, has secured accelerated approval for adult patients with mantle cell lymphoma (MCL) — a typically aggressive, rare, form of blood cancer — who have received at least one prior therapy.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,700+ biopharma pros reading Endpoints daily — and it's free.

What does $62B buy you these days? A lot, says Take­da ex­ecs as the phar­ma play­er promis­es a block­buster R&D fu­ture

First comes the $62 billion buyout. Then comes the asset auction and reorganization to pay down debt. Now comes the detailed pledge of a bigger, brighter future in drug development.

That’s where Takeda finds itself on R&D day today, about 11 months after closing on their Shire acquisition. R&D chief Andy Plump is joining CEO Christophe Weber and other top members of the team to outline a new set of priorities in the greatly expanded pipeline at Takeda, which has jumped into the top ranks of the world’s pharma giants in the wake of the Shire deal.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,700+ biopharma pros reading Endpoints daily — and it's free.

GSK's asth­ma bi­o­log­ic Nu­cala scores in rare blood dis­or­der study

GlaxoSmithKline’s asthma drug Nucala, which received a resounding FDA rejection for use in chronic obstructive pulmonary disease (COPD) last year, has shown promise in a rare blood disorder.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,700+ biopharma pros reading Endpoints daily — and it's free.

Mer­ck buys a fledg­ling neu­rode­gen­er­a­tive biotech spawned by an old GSK dis­cov­ery al­liance. What’s up with that?

Avalon Ventures chief Jay Lichter has a well-known yen for drug development programs picked up in academia. And what he found in Haoxing Xu’s lab at the University of Michigan pricked his interest enough to launch one of his umbrella biotechs in San Diego.

Xu’s work laid the foundation for Avalon to launch Calporta, which has been working on finding small molecule agonists of TRPML1 (transient receptor potential cation channel, mucolipin subfamily, member 1) for lysosomal storage disorders. And that pathway, they believe, points to new approaches on major market neurodegenerative diseases like Parkinson’s, ALS and Alzheimer’s.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,700+ biopharma pros reading Endpoints daily — and it's free.

(Image: Associated Press)

No­var­tis scores its lat­est FDA OK — this time for a new sick­le cell dis­ease drug picked up in a $665M deal

Novartis’ decision to buy Oklahoma-based biotech Selexys 3 years ago for up to $665 million has paid off with an FDA approval today.

Blessed with the FDA’s breakthrough drug designation for a speedy review, the pharma giant has pinned down an approval for crizanlizumab, a new therapy designed to reduce the frequency of painful incidents of vaso-occlusive crises among sickle cell disease patients 16 or older.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,700+ biopharma pros reading Endpoints daily — and it's free.